Pfizer Takes First Small Step Into Longevity Field With Gero Collaboration
A Milestone For Field, Says Biotech
Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.
You may also be interested in...
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."
Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.